Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Madrigal Pharmaceuticals Inc MDGL

Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-ß (THR-ß) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic... see more

Recent & Breaking News (NDAQ:MDGL)

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire October 31, 2024

Madrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

GlobeNewswire October 30, 2024

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

GlobeNewswire October 21, 2024

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

GlobeNewswire October 18, 2024

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

GlobeNewswire October 2, 2024

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

GlobeNewswire October 1, 2024

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra(TM) (resmetirom)

GlobeNewswire September 30, 2024

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 26, 2024

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire August 7, 2024

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

GlobeNewswire August 2, 2024

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

GlobeNewswire July 24, 2024

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra(TM) (resmetirom) Presented at the EASL Congress

GlobeNewswire June 6, 2024

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 5, 2024

Madrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

GlobeNewswire May 29, 2024

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire May 7, 2024

Madrigal Statement on the Passing of Dr. Stephen Harrison

GlobeNewswire April 24, 2024

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

GlobeNewswire April 23, 2024

6 Stocks Positioned to Soar as Investors Focus on MASH

TheNewsWire April 22, 2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 16, 2024